Forgot your password?
New User?
Remember me
banner banner

united states biological header

table of contents

 Cholesterol Lowering Drug Candidate: the PCSK9-inhibitor REGN727


NEW Products


Catalog #

Product Name

A2221 Amphotericin B (Fungizone, Fungilin, Ampho-Moronal)
C5069-66A Chorionic Gonadotropin, Human, beta (hCGb)
D9546 Drop-out Mix Modified w/Succinic Acid and Thiamine w/o Aminobenzoic Acid, Asparagine, Glycine, Methionine and Yeast Nitrogen Base (Powder)
L1501-02 L-15ex Medium Modified w/Cupric Sulfate w/o Phenol Red
M2162-07 Mammary Epithelial Basal Medium MCDB 170 w/o Calcium, Phenol Red (Powder)
P1001-37S1 p70 S6 kinase




Tris is an abbreviation for tris(hydroxymethyl)aminomethane, with the formula (HOCH2)3CNH2. Tris is widely used as a component of buffer solutions, such as in TAE (composed of Tris, acetic acid and EDTA) and TBE (composed of Tris, boric acid and EDTA) buffers, especially for solutions of nucleic acids.

The useful buffer range for Tris (pH 7-9) coincides with the typical physiological pH of most living organisms. This makes Tris one of the most commonly used buffers in the biology/biochemistry laboratory.



lab glassware

Catalog #

Product Name

T8600 Tris Base Ultrapure
T8600-05 Tris Acetate
T8600-20 Tris Hydrochloride Buffer (Tris HCl), 1M, pH 7.5
T8600-21 Tris Hydrochloride Buffer (Tris-HCl), 1M, pH 8.0
T8601 Tris Base USP
T8650 Tris Hydrochloride (Tris HCl)



FEATURED CD47: Promising target for solid tumor treatment

Metastatic carcinoma of the brain
MRI image of metastatic carcinoma of the brain

In a recent article in the Proceedings of the National Academy of Sciences, Willingham et al., have found that CD47 is expressed on a wide range of human solid tumors, perhaps as the one constant change in all human aggressive neoplasms. The authors have also validated one function of CD47 on these cancers, as a “don’t eat me” signal. CD47 therefore serves as an attractive target for cancer therapies. They further demonstrated that monoclonal antibodies that block CD47 are effective for treating human solid tumors in vitro and in vivo.



Read More



ARTICLE A Novel Cholesterol Lowering Drug Candidate: the PCSK9-inhibitor REGN727


An ongoing Phase I clinical trial for a new, experimental cholesterol-fighting drug is displaying very encouraging results.1 Researchers have known for some time that PCSK9 (proprotein convertase substilisin/kexin type 9) is a protein that binds to the Low-Density Lipoprotein Receptor (LDLR), which prevents LDLR from binding to LDL and removes it from circulation.2-4 Too much LDL (bad) cholesterol circulating in the blood can lead to the thickening of artery walls, which makes them less flexible and therefore impairs their function and increases the risk of heart disease.

Catalog #

Product Name




P9052-29 Proprotein Convertase 9 (PC9, PCSK9, Neural Apoptosis-Regulated Convertase 1, NARC1) Mab Rt x Mo
P9052-40 Proprotein Convertase Subtilisin Kexin 9 (PCSK9, NARC-1 Pab Rb x Hu
L2601-01 Lipoprotein Receptor, Low Density (LDLR, LDL Receptor) Pab Rb x Hu
L2601-10 Lipoprotein, Low Density (LDL) Mab Mo x Hu


Read more